Johnson & Johnson (JNJ)
Johnson & Johnson discontinues dengue drug study
Johnson & Johnson said on Friday it will discontinue its mid-stage field study evaluating the efficacy of its antiviral drug candidate for the prevention of dengue.
2 Smart Income Stocks to Buy Right Now
These storied companies have a lot to offer different investors.
Why Johnson & Johnson (JNJ) Dipped More Than Broader Market Today
Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.
J&J to invest more than $2 billion in new manufacturing facility
Johnson & Johnson said on Tuesday it will invest more than $2 billion to build a new manufacturing facility at Wilson, North Carolina.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
Johnson & Johnson (JNJ) closed at $162.78 in the latest trading session, marking a -0.27% move from the prior day.
J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?
We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.
J&J subsidiary files for bankruptcy for third time to settle talc lawsuits
Under the proposal, Johnson & Johnson will pay $8B to claimants over 25 years.
Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time
The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.
Johnson & Johnson: A Sell-Rated Dividend King
Johnson & Johnson (JNJ) is showing signs of a topping pattern with negative divergences in momentum indicators, suggesting potential price weakness ahead. The stock is expensive based on forward P/E and free cash flow yield, with poor growth prospects and negative earnings revisions. Despite favorable seasonality, JNJ may underperform in a risk-on market environment as defensive sectors lag.
J&J talc subsidiary files third bankruptcy case in attempt to resolve cancer lawsuits
CNBC's Becky Quick reports on the latest news.
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson is capturing strong demand across its pharmaceutical and medtech portfolio. New product launches and an extensive pipeline of candidate drugs support a positive growth outlook.
